Novo Nordisk A/S – Share repurchase programme
Bagsværd, Denmark, 31 October 2019 – On 9 August 2019, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 1 February 2019.
Under the programme initiated 9 August 2019, Novo Nordisk has repurchased B shares for an amount up to DKK 2.6 billion in the period from 9 August 2019 to 30 October 2019. The programme is now concluded.
Since the announcement as of 28 October 2019, the following transactions have been made:
|Accumulated, last announcement||7,068,950||2,474,809,134|
|28 October 2019||115,000||364.32||41,896,513|
|29 October 2019||115,000||365.97||42,087,028|
|30 October 2019||111,461||369.70||41,207,239|
|Accumulated under the programme||7,410,411||2,599,999,914|
The details for each transaction made under the share repurchase programme are published on novonordisk.com.
With the transactions stated above, Novo Nordisk owns a total of 37,970,455 B shares of DKK 0.20, corresponding to 1.6% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,400,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning 1 February 2019. As of 30 October, Novo Nordisk has since 1 February 2019 repurchased a total of 30,811,423 B shares at an average share price of DKK 332.18 per B share equal to a transaction value of DKK 10,234,953,368.
|Anne Margrethe Hauge||+45 4442 email@example.com|
|Ken Inchausti (US)||+1 609 240 firstname.lastname@example.org|
|Peter Hugreffe Ankersen||+45 3075 email@example.com|
|Valdemar Borum Svarrer||+45 3079 firstname.lastname@example.org|
|Ann Søndermølle Rendbæk||+45 3075 email@example.com|
|Kristoffer Due Berg (US)||+1 609 235 firstname.lastname@example.org|
Company announcement No 61 / 2019
Upcoming Life Sciences Events
- November 2019
- Austria: 3rd Annual Inhalation & Respiratory Drug Products Summit
- Duesseldorf: DxPx Conference 2019
- Krakow: Life Science Open Space 2019